Rubicon Research Limited Q4 FY2026 Audited Financial Results.
Rubicon Research Limited, a provider of contract formulation development services to pharmaceutical companies, announced its Q4 FY2026 and FY2026 results.
The Company reported a strong financial performance for the quarter and year ended March 31, 2026, with net profit for the quarter rising 112 percent.
Revenue growth for the company was broad-based, with the top 5 products contributing 39% of revenue in Q4 FY2026, up from 34% in Q1 FY2026.
USD revenue for Q4 FY2026 stood at $56 million, up 35% year-on-year, with approximately 98% of total revenue denominated in USD.
Revenue from operations for Q4 FY2026 increased 44 percent to ₹5.14 billion compared to ₹3.58 billion in Q4 FY2025, driven by robust growth across the pharmaceutical product portfolio.
Rubicon reported a 112% rise in Q4 FY2026 net profit to ₹768 million and an 84% increase in FY2026 net profit to ₹2.47 billion.
EPS (Earnings Per Share) for the year increased to ₹15.52 from ₹8.82 in the prior year.
The board has recommended a dividend of 150%, which is ₹1.50 per share. This amounts to 10% payout ratio.
Management explained that the Pithampur site has been qualified and filed with the USFDA, with production ramp-up expected in Q1 CY27.
It also said that revenue traction is likely to continue to be stronger than anticipated, which in turn would require a commensurate increase in revenue from outsourced manufacturing as compared to what we had previously envisaged.
Company Overview & Others
Overview: Rubicon Research Ltd. is a pharmaceutical formulations company, driven by innovation through research and development (R&D). The company planned an IPO in October 2025.
Market Cap: Rubicon Research has a total market capitalization of ₹16,500 crore as of May 30, 2026, according to the NSE data.
Technical: The stock is well placed above its 20-, 50-, and 100-day simple moving averages (SMAs).
Price Performance: On a year-to-date basis, Rubicon Research’s share increased by 48%. However, the company’s shares have been trading 28% higher over the last three months.
Also Read
Disclaimer: This article is purely for informational purposes. While much time and effort is made to provide the information, I (Vishal Dalwadi) or (FinBlab) do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.